You are here

Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years

Last updated on March 15, 2019

FOR MORE INFORMATION
Study Location
Grieskirchner Strasse 17
Wels, , 4600 Austria
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Tick-borne Encephalitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
1-15 year
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Male and female children and adolescents will be eligible for participation in this study
if:

- they are aged 1 year (from the 1st birthday) to 16th birthday);

- they are clinically healthy, (i. e. the physician would have no reservations
vaccinating with FSME-IMMUN NEW outside the scope of a clinical trial);

- their parents/legal guardians understand the nature of the study and agree to its
provisions;

- written informed consent is available from both parents/legal guardians,

- for Germany/Austria: additional written informed consent is available for children
older than 8 years

- they or their parents/legal guardians agree to keep a volunteer diary.

For safety reasons, female volunteers who have reached sexual maturity at study start have
to meet the following additional inclusion criteria:

- negative pregnancy test at study entry;

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Children and adolescents will be excluded from participation in this study if they:

- have a history of any TBE vaccination;

- have a history of TBE infection;

- have a history of allergic reactions to one of the components of the vaccine;

- suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment
(e.g. systemic corticosteroids, chemotherapeutics) that can be expected to influence
immunological functions;

- are known to be HIV positive (a special HIV test is not required for the purpose of
the study);

- have received banked blood or immunoglobulins within one month of study entry;

- have a history of vaccination against yellow fever and/or Japanese B-encephalitis;

- suffer from hemorrhagic diathesis;

- are participating simultaneously in another clinical trial;

- if female: are pregnant or breastfeeding.

Volunteers who meet the inclusion/exclusion criteria, but have a febrile illness (body
temperature > 38°C) at the scheduled time of vaccination, will not be vaccinated before
their body temperature returns to normal.

Volunteers who have received any other vaccination within 4 weeks prior to visit 1 will not
be vaccinated until an interval of 4 weeks has passed. In this case visit 1 will take place
separately.

If volunteers have received antipyretics within 4 hours prior to the intended TBE
vaccination, the vaccination should be performed at a later time.

Volunteers who have a positive TBE antibody value prior to the first vaccination will be
excluded from the statistical analysis of the primary endpoint.

NCT00161863
Pfizer
Completed
Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now